Status:

UNKNOWN

Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic Impairment

Lead Sponsor:

Jiangsu HengRui Medicine Co., Ltd.

Conditions:

Hepatic Impairment

Eligibility:

All Genders

18-65 years

Phase:

PHASE1

Brief Summary

Study to evaluate pharmacokinetics, pharmacodynamics and safety of SHR4640 in patients with mild, moderate hepatic impairment and normal liver function in phase I clinical study.

Eligibility Criteria

Inclusion

  • \-
  • All subjects:
  • Signing the informed consent forms.
  • 18 years to 65 years (inclusive).
  • Body mass index should be between 18 and 30 kg/m2 (inclusive).
  • No medication was used before screening#or stable medication for 4 weeks.
  • Normal liver function:
  • • Clinical laboratory tests during the screening period were normal or the abnormality has no clinical significance.
  • Hepatic impaired subjects:
  • Child-Pugh Classification score clinically determined as mild or moderate hepatic impairment.
  • Liver damage due to primary liver disease.

Exclusion

  • \-
  • All subjects:
  • • Subject known or suspected of being sensitive to the study drugs or its ingredient.
  • Normal liver function:
  • Previous history of liver function impairment, or physical examination and laboratory examination at screening indicated the presence or possibility of liver function impairment.
  • Hepatitis B surface antigen (HBsAg) positive or Anti-hepatitis C virus (HCV) antibody or hepatitis C core antigen positive within 3 months prior to administration.
  • Hepatic impaired subjects:
  • Suspected or diagnosed as liver cancer or with other malignant tumors.
  • Drug induced liver injury#acute liver injury#liver transplantation history.
  • Subjects with hepatic failure,or severe complications caused by Hepatocirrhosis.

Key Trial Info

Start Date :

August 4 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2022

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT04305392

Start Date

August 4 2020

End Date

December 1 2022

Last Update

August 10 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Meixia Wang

Beijing, Beijing Municipality, China, 100069